Report forecast the solid tumor testing market in
the US to grow at a CAGR of 11.1% during the period 2016-2020.
Solid tumor testing or screening is done for the
early detection of cancer, enabling effective treatment measures to avoid the
spread of cancerous cells throughout the body. The testing procedure involves
testing of samples such as urine, blood, and other bodily substances. Further,
cancer testing also involves conducting genetic tests to analyze certain gene
mutations that are linked to certain cancer types. Biopsy, colonoscopy,
Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests
that are performed for cancer screening.
The report covers the present scenario and the
growth prospects of the solid tumor testing market in the US for 2016-2020. To
calculate the market size, the report considers the revenue generated from the
sales of solid tumor testing products, such as assays or kits and bench-top
instruments.
The market is divided into the following
segments based on cancer types:
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other (including pancreatic cysts and thyroid nodules)
According to the report, Proteins and genes control
various functions of the body. Any defect in a particular protein or gene
structure will result in the occurrence of specific disorders. The development
of personalized drugs depends on the identification and study of protein and
gene expressions. These personalized medicines are regulated and labeled along
with a specific diagnostic test, referred to as companion diagnostic. This
tailored approach facilitates better therapeutic outcomes, owing to specific
screening and selection of the patient population. This factor boosts the
demand for personalized medicines, which, in turn, would drive the adoption of
solid tumor testing.
Further, the report states that the regulatory and
reimbursement scenario in the country has been impeding market growth ever
since the government introduced medical device excise tax and cuts in bundled
payments, which has restricted the use of insurance by customers.
Solid Tumor Testing Market in the US 2016-2020,
has been prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its growth
prospects over the coming years. The report also includes a discussion of the
key vendors operating in this market.
key players in the Solid Tumor Testing Market in
the US: Abbott Molecular, Agilent Technologies (Dako), Beckman Coulter and
Roche Diagnostics.
Other Prominent Vendors in the market are: 20/20
GeneSystems, Adaptive Biotechnologies, Advanced Cell Diagnostics, Affymetrix,
Agena Bioscience, Ambry Genetics, ApoCell, Avant Diagnostics, Biological
Dynamics, Boditech Med, Becton, Dickinson and Company (BD), Biocare Medical,
Bio-Rad Laboratories, Castle Biosciences, CDx Diagnostics, Celerus Diagnostics,
Cancer Genetics, Caris Life Sciences, Clarient Diagnostic Services, DiaTech
Oncology, Enzo Biochem, Epic Sciences, EDP Biotech, Eutropics Pharmaceuticals,
Fujirebio Diagnostics, Genalyte, Hologic, Janssen Diagnostics, Myriad Genetics,
Omnyx, OxfordGene Technology, Oncospire Genomics, OncoCyte, OvaGene Oncology,
Pathway Genomics, Quest Diagnostics, QIAGEN, RiboMed Biotechnologies, Sequenom,
Siemens Healthcare Diagnostics, Thermo Fisher Scientific, Tosoh Bioscience and
TrimGen.
Market driver
- High demand for personalized medicines
- For a full, detailed list, view our report
Market challenge
- Regulatory issues
- For a full, detailed list, view our report
Market trend
- Ready-to-use reagents
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 50 pages and 28 Exhibit “Solid
Tumor Testing Market in the US 2016 - 2020” report covers Executive summary, Scope
of the report, Market research methodology, Introduction, Market Overview,
Market Landscape, Healthcare reform in US, Reimbursement and coverage: An
overview, Market segmentation by technology, Market segmentation by cancer
type, Market drivers, Impact of drivers, Market challenges, Impact of drivers
and challenges, Market trends, Vendor landscape, Appendix.
For
more information Visit at: http://mrr.cm/oth
Related Report;
Cardiac Medical Devices Market in the US 2016-2020 -
Visit at - http://mrr.cm/ot7
Find all Healthcare report at : http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.